Table 1.
Recipient characteristics at the time of liver transplantation
| Case | Age | Gender | AB0 | BMI | Indication | Real MELD | MELD correct | UNOS | Wating List(d) | Year LT | HCC criteria | Downstaging type (No.) |
| 1 | 62 | M | 0 | 27 | HCC/HBV | 26 | 36 | 2A | 37 | 2007 | MILAN IN | LOC(1)1 |
| 2 | 65 | M | B | 21 | HCC/HBV | 16 | 39 | 3 | 522 | 2007 | MILAN IN | LOC(1) + SUR(1) |
| 3 | 54 | M | A | 22 | HCC/HBV | 10 | 33 | 3 | 513 | 2007 | MILAN IN | LOC(1) |
| 4 | 45 | M | A | 24 | HCC/HBV | 14 | 34 | 2B | 419 | 2007 | MILAN OUT | LOC (3) |
| 5 | 62 | M | 0 | 29 | HCC/HBV | 12 | 33 | 3 | 445 | 2008 | MILAN OUT | LOC (2) |
| 6 | 53 | M | 0 | 28 | HCC/HBV | 12 | 35 | 2B | 515 | 2008 | MILAN IN | LOC (1) |
| 7 | 45 | M | A | 23 | HCV/HBV | 24 | 24 | 2A | 101 | 2005 | ||
| 8 | 64 | M | B | 27 | HBV/HCV | 33 | 33 | 2A | 478 | 2005 | ||
| 9 | 26 | M | A | 23 | HBV | 23 | 23 | 2B | 742 | 2005 | ||
| 10 | 64 | M | A | 22 | HCC/HBV | 11 | 23 | 2B | 144 | 2005 | MILAN IN | LOC (2) |
| 11 | 65 | F | B | 25 | HCC/HBV | 12 | 24 | 2A | 195 | 2006 | MILAN IN | LOC (2) |
| 12 | 56 | M | A | 24 | HCC/HBV | 10 | 24 | 2B | 217 | 2006 | MILAN OUT | LOC (5) |
| 13 | 61 | F | 0 | 23 | HCC/HBV | 14 | 30 | 2B | 352 | 2006 | MILAN IN | LOC (2) |
| 14 | 59 | M | A | 24 | HBV | 30 | 30 | 2B | 118 | 2007 | ||
| 15 | 48 | F | A | 27 | CBS | 21 | 33 | 2A | 82 | 2007 | ||
| 16 | 65 | M | A | 24 | HCC/HBV | 8 | 25 | 2B | 358 | 2009 | MILAN IN | LOC (2) |
| 17 | 57 | M | A | 30 | HCC/HBV | 14 | 39 | 2B | 576 | 2009 | MILAN OUT | LOC (7) |
| 18 | 55 | M | B | 28 | HCC/HBV | 18 | 26 | 2B | 38 | 2009 | MILAN IN | LOC (3) |
| 19 | 65 | M | A | 24 | HCC/HBV | 7 | 25 | 2B | 371 | 2009 | MILAN IN | LOC (3) |
| 20 | 63 | M | A | 28 | HCC/HBV | 16 | 25 | 2B | 1962 | 2010 | MILAN IN | LOC (2) |
| 21 | 60 | M | A | 34 | HCC/HBV | 10 | 27 | 2B | 330 | 2010 | MILAN OUT | LOC (1) + SUR (1) |
| 22 | 61 | M | A | 24 | HBV | 11 | 11 | 3 | 855 | 2010 | ||
| 23 | 67 | M | 0 | 19 | HBV | 16 | 16 | 2B | 742 | 2004 | ||
| 24 | 55 | M | A | 24 | HBV | 17 | 17 | 3 | 127 | 2004 | ||
| 25 | 60 | F | 0 | 29 | HBV/HCV | 17 | 17 | 2B | 961 | 2004 | ||
| 26 | 55 | M | A | 26 | HCC/HBV | 10 | 20 | 3 | 748 | 2005 | MILAN IN | LOC (1) |
| 27 | 54 | M | A | 27 | HCC/HBV | 13 | 19 | 3 | 134 | 2006 | MILAN OUT | LOC (2) |
| 28 | 67 | M | 0 | 22 | HCC/HBV | 12 | 29 | 3 | 575 | 2009 | MILAN IN | LOC (1) + SUR (1) |
1
LOC: Locoregional therapy [transcatheter arterial chemoembolization (TACE) and/or radiofrequency ablation (RITA)]. SUR: Surgery; MELD: Model for end-stage disease; BMI: Body mass index; LT: Liver transplantation; HCC: Hepatocellular carcinoma; CBS: Secondary biliary cirrhosis; HCV: Hepatitis C virus.